The Defense Biological Product Assurance Office (DBPAO), a component of the Joint Program Executive Office for Chemical and Biological Defense, has announced the development of a Biological Select Agents and Toxins (BSAT) [Read more]
President Trump’s fiscal year 2018 budget, released last week, zeroes out funding for the National Biodefense Analysis and Countermeasures Center (NBACC) in Frederick, Maryland and calls for its closure. The NBACC is part [Read more]
The Defense Threat Reduction Agency is seeking innovative technologies to accomplish automated text processing and visual analytics for biological materials situational awareness in support of the Biological Materials Information Program (BMIP). BMIP [Read more]
The Defense Threat Reduction Agency (DTRA) has announced intentions award a sole source contract to Technology Management Company (TMC) to implement science engagements in Uzbekistan to promote biological safety and security of [Read more]
Battelle and Nanotherapeutics, Inc. announced today that the organizations have entered an alliance to bring together core research, development, test and evaluation (RDT&E) and manufacturing capabilities needed to expedite the development of [Read more]
The Office of the Biomedical Advanced Research and Development Authority (BARDA) is seeking information on sources for developing and manufacturing Ebola vaccines and therapeutics, specifically vaccines targeting Zaire Ebolavirus. Infections by Ebola [Read more]
Elusys Therapeutics, Inc. has received payment from the U.S. federal government for completing the second delivery of its medical countermeasure for inhalational anthrax, according to a Jan. 24 statement by the company. [Read more]
The National Institute of Allergy and Infectious Diseases (NIAID) will be soliciting proposals under a new Omnibus Broad Agency Announcement (BAA) expected to be formally released on February 21, 2017. The BAA [Read more]
While the natural prevalence of antimicrobial resistance (AMR) in traditional biowarfare agents remains relatively low, the potential for genetic manipulation, acquired or deliberate, makes the possibility of a resistant threat a necessary [Read more]
Scientists from NIH’s National Institute of Allergy and Infectious Diseases, working with colleagues from the University of Washington and Columbia University, have published study results on a new Ebola virus (EBOV) mouse [Read more]
© 2017 Global Biodefense